Skip to main content
Erschienen in: The Patient - Patient-Centered Outcomes Research 2/2009

01.06.2009 | Original Research Article

Health-Related Quality of Life and Quality of Life in Type 2 Diabetes

Relationships in a Cross-Sectional Study

Erschienen in: The Patient - Patient-Centered Outcomes Research | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

Background and objectives: Health-related quality of life (HR-QOL) and quality of life (QOL) are increasingly being examined as outcomes in assessments among patients with type 2 diabetes mellitus. However, there is a lack of standardization in interpreting the two outcomes and insufficient appreciation of the differences between HR-QOL and QOL. This study reports relationships between two instruments of HR-QOL and an instrument of QOL in a cross-sectional study of patients with type 2 diabetes.
Methods: Patients with type 2 diabetes at the outpatient clinics of a university hospital completed measures of generic health status (12-item Short-Form Health Survey [SF-12], version 2 and EQ-5D) and diabetes-specific QOL (Audit of Diabetes Dependent Quality of Life [ADDQoL]). Patient-reported data were merged with retrospective clinical data including glycosylated hemoglobin (HbA1c), co-morbidities, diabetes complications score, body mass index (BMI), and others, obtained from electronic medical records. A path model of our hypothesized relationships between the physical and psychological components of HR-QOL, overall HR-QOL, and QOL was tested in addition to examining bivariate correlations between these constructs. The fit of the path model was assessed using multiple indexes of fit, including an overall chi-squared (χ2) test, the Comparative Fit Index (CFI), the Tucker-Lewis Index (TLI), and the Root Mean Square Error Approximation (RMSEA). The differences in the association between clinical, medical history and sociodemographic variables with HR-QOL and QOL were explored employing univariate t-tests and ANOVAs as well as multiple regression models.
Results: The usable response rate was 44.3% (n = 385). The mean HbA1c of respondents was 7.2% (±1.4), mean duration of diabetes was 10.2 (±9.1) years, and 62.1% were obese (BMI ≥30kg/m2). About 49% of respondents were taking oral medications only, 31.7% were taking oral medications and insulin, and 9.4% were taking insulin only. Spearman correlations of the EQ-5Dindex were 0.640 with the SF Physical Component Score (PCS)-12, 0.534 with the SF Mental Component Score (MCS)-12, and 0.316 with the ADDQoL (all p<0.001). A path analytic model relating SF-12 scores with EQ-5Dindex and ADDQoL scores exhibited good fit (χ2 = 1.32; p = 0.250; CFI = 0.99; TLI = 0.99; RMSEA = 0.03). Insulin use and diabetes-related complications were significantly associated with poorer scores on all measures. Only ADDQoL scores were significantly better among those with the American Diabetes Association-recommended HbA1c level of <7.0% (p = 0.002). Obesity was significantly associated with impaired SF-12 and EQ-5Dindex scores but not ADDQoL scores, while depressive symptoms were significantly associated with poorer scores on all these measures. The included explanatory variables explained a greater proportion of the variance in HR-QOL (PCS-12, MCS-12, EQ-5Dindex) than in QOL (ADDQoL) scores.
Conclusion: The study found that HR-QOL measures showed small correlations with the impact of diabetes on QOL. The fit statistics supported the hypothesized relationships in the path model, and provided empirical evidence that HR-QOL is a subset of QOL. In comparison to HR-QOL, QOL was less explained by the included explanatory variables, suggesting a greater influence on QOL by factors not accounted for in the present study.
Literatur
1.
Zurück zum Zitat Polonsky WH. Understanding and assessing diabetes-specific quality of life. Diabetes Spectrum 2000; 13(1): 36–41 Polonsky WH. Understanding and assessing diabetes-specific quality of life. Diabetes Spectrum 2000; 13(1): 36–41
2.
Zurück zum Zitat Rothman ML, Beltran P, Cappelleri JC, et al. Patient-reported outcomes: conceptual issues. Value Health 2007; 10Suppl. 2: S66–75PubMedCrossRef Rothman ML, Beltran P, Cappelleri JC, et al. Patient-reported outcomes: conceptual issues. Value Health 2007; 10Suppl. 2: S66–75PubMedCrossRef
3.
Zurück zum Zitat Health and Quality of Life Outcomes. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006; 4: 79 [online]. Available from URL http://www.hqlo.com/content/4/1/79 [Accessed 2006 Dec 5] Health and Quality of Life Outcomes. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006; 4: 79 [online]. Available from URL http://​www.​hqlo.​com/​content/​4/​1/​79 [Accessed 2006 Dec 5]
4.
Zurück zum Zitat Jacobson AM, de Groot M, Samson JA. The evaluation of two measures of quality of life in patients with type I and type II diabetes. Diabetes Care 1994; 17(4): 267–74PubMedCrossRef Jacobson AM, de Groot M, Samson JA. The evaluation of two measures of quality of life in patients with type I and type II diabetes. Diabetes Care 1994; 17(4): 267–74PubMedCrossRef
5.
Zurück zum Zitat Anderson RM, Fitzgerald JT, Wisdom K, et al. A comparison of global versus disease-specific quality-of-life measures in patients with NIDDM. Diabetes Care 1997; 20(3): 299–305PubMedCrossRef Anderson RM, Fitzgerald JT, Wisdom K, et al. A comparison of global versus disease-specific quality-of-life measures in patients with NIDDM. Diabetes Care 1997; 20(3): 299–305PubMedCrossRef
6.
Zurück zum Zitat Gandhi GY, Murad MH, Fujiyoshi A, et al. Patient-important outcomes in registered diabetes trials. JAMA 2008; 299(21): 2543–9PubMedCrossRef Gandhi GY, Murad MH, Fujiyoshi A, et al. Patient-important outcomes in registered diabetes trials. JAMA 2008; 299(21): 2543–9PubMedCrossRef
7.
Zurück zum Zitat Rubin RR. Diabetes and quality of life. Diabetes Spectrum 2000; 13(1): 21–3 Rubin RR. Diabetes and quality of life. Diabetes Spectrum 2000; 13(1): 21–3
8.
Zurück zum Zitat Katon WJ, Rutter C, Simon G, et al. The association of comorbid depression with mortality in patients with type 2 diabetes. Diabetes Care 2005; 28(11): 2668–72PubMedCrossRef Katon WJ, Rutter C, Simon G, et al. The association of comorbid depression with mortality in patients with type 2 diabetes. Diabetes Care 2005; 28(11): 2668–72PubMedCrossRef
9.
Zurück zum Zitat Kleefstra N, Landman GW, Houweling ST, et al. Prediction of mortality in type 2 diabetes from health-related quality of life (ZODIAC-4). Diabetes Care 2008; 31(5): 932–3PubMedCrossRef Kleefstra N, Landman GW, Houweling ST, et al. Prediction of mortality in type 2 diabetes from health-related quality of life (ZODIAC-4). Diabetes Care 2008; 31(5): 932–3PubMedCrossRef
10.
Zurück zum Zitat The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329(14): 977–86CrossRef The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329(14): 977–86CrossRef
11.
Zurück zum Zitat United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131): 837–53CrossRef United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131): 837–53CrossRef
12.
Zurück zum Zitat The Diabetes Control and Complications Trial Research Group. Influence of intensive diabetes treatment on quality-of-life outcomes in the diabetes control and complications trial. Diabetes Care 1996; 19(3): 195–203CrossRef The Diabetes Control and Complications Trial Research Group. Influence of intensive diabetes treatment on quality-of-life outcomes in the diabetes control and complications trial. Diabetes Care 1996; 19(3): 195–203CrossRef
13.
Zurück zum Zitat United Kingdom Prospective Diabetes Study Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 1999; 22(7): 1125–36CrossRef United Kingdom Prospective Diabetes Study Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 1999; 22(7): 1125–36CrossRef
14.
Zurück zum Zitat Bradley C. Importance of differentiating health status from quality of life. Lancet 2001; 357(9249): 7–8PubMedCrossRef Bradley C. Importance of differentiating health status from quality of life. Lancet 2001; 357(9249): 7–8PubMedCrossRef
15.
Zurück zum Zitat Speight J. Assessing the impact of diabetes screening on quality of life or quality of health? Semantics are important. Diabetes Care 2002; 25(10): 1893–4PubMedCrossRef Speight J. Assessing the impact of diabetes screening on quality of life or quality of health? Semantics are important. Diabetes Care 2002; 25(10): 1893–4PubMedCrossRef
17.
Zurück zum Zitat Kind P. The EuroQoL instrument: an index of health-related quality of life. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. Philadelphia (PA): Lippincott-Raven, 1996: 191–201 Kind P. The EuroQoL instrument: an index of health-related quality of life. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. Philadelphia (PA): Lippincott-Raven, 1996: 191–201
18.
Zurück zum Zitat Bradley C, Todd C, Gorton T, et al. The development of an individualized questionnaire measure of perceived impact of diabetes on quality of life: the ADDQoL. Qual Life Res 1999; 8(1-2): 79–91PubMedCrossRef Bradley C, Todd C, Gorton T, et al. The development of an individualized questionnaire measure of perceived impact of diabetes on quality of life: the ADDQoL. Qual Life Res 1999; 8(1-2): 79–91PubMedCrossRef
19.
Zurück zum Zitat Garratt AM, Schmidt L, Fitzpatrick R. Patient-assessed health outcome measures for diabetes: a structured review. Diabet Med 2002; 19(1): 1–11PubMedCrossRef Garratt AM, Schmidt L, Fitzpatrick R. Patient-assessed health outcome measures for diabetes: a structured review. Diabet Med 2002; 19(1): 1–11PubMedCrossRef
21.
22.
Zurück zum Zitat Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005; 43(3): 203–20PubMedCrossRef Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005; 43(3): 203–20PubMedCrossRef
23.
Zurück zum Zitat Ware Jr J, Kosinski M, Keller SD, et al. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34(3): 220–33PubMedCrossRef Ware Jr J, Kosinski M, Keller SD, et al. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34(3): 220–33PubMedCrossRef
24.
Zurück zum Zitat Ware Jr J, Kosinski M, Turner-Bowker DM, et al. How to score Version 2 of the SF-12® Health Survey (with a supplement documenting Version 1). Lincoln (RI): Quality-Metric Inc., 2002 Ware Jr J, Kosinski M, Turner-Bowker DM, et al. How to score Version 2 of the SF-12® Health Survey (with a supplement documenting Version 1). Lincoln (RI): Quality-Metric Inc., 2002
25.
Zurück zum Zitat Rubin RR, Peyrot M. Quality of life and diabetes. Diabetes Metab Res Rev 1999; 15(3): 205–18PubMedCrossRef Rubin RR, Peyrot M. Quality of life and diabetes. Diabetes Metab Res Rev 1999; 15(3): 205–18PubMedCrossRef
26.
Zurück zum Zitat Nerenz DR, Repasky DP, Whitehouse FW, et al. Ongoing assessment of health status in patients with diabetes mellitus. Med Care 1992; 30(5 Suppl.): MS112–24PubMedCrossRef Nerenz DR, Repasky DP, Whitehouse FW, et al. Ongoing assessment of health status in patients with diabetes mellitus. Med Care 1992; 30(5 Suppl.): MS112–24PubMedCrossRef
27.
Zurück zum Zitat Glasgow RE, Ruggiero L, Eakin EG, et al. Quality of life and associated characteristics in a large national sample of adults with diabetes. Diabetes Care 1997; 20(4): 562–7PubMedCrossRef Glasgow RE, Ruggiero L, Eakin EG, et al. Quality of life and associated characteristics in a large national sample of adults with diabetes. Diabetes Care 1997; 20(4): 562–7PubMedCrossRef
28.
Zurück zum Zitat de Sonnaville JJ, Snoek FJ, Colly LP, et al. Well-being and symptoms in relation to insulin therapy in type 2 diabetes. Diabetes Care 1998; 21(6): 919–24PubMedCrossRef de Sonnaville JJ, Snoek FJ, Colly LP, et al. Well-being and symptoms in relation to insulin therapy in type 2 diabetes. Diabetes Care 1998; 21(6): 919–24PubMedCrossRef
29.
Zurück zum Zitat Sundaram M, Kavookjian J, Patrick JH, et al. Quality of life, health status and clinical outcomes in type 2 diabetes patients. Qual Life Res 2007; 16(2): 165–77PubMedCrossRef Sundaram M, Kavookjian J, Patrick JH, et al. Quality of life, health status and clinical outcomes in type 2 diabetes patients. Qual Life Res 2007; 16(2): 165–77PubMedCrossRef
30.
Zurück zum Zitat Ford ES, Moriarty DG, Zack MM, et al. Self-reported body mass index and health-related quality of life: findings from the Behavioral Risk Factor Surveillance System. Obes Res 2001; 9(1): 21–31PubMedCrossRef Ford ES, Moriarty DG, Zack MM, et al. Self-reported body mass index and health-related quality of life: findings from the Behavioral Risk Factor Surveillance System. Obes Res 2001; 9(1): 21–31PubMedCrossRef
31.
Zurück zum Zitat Hassan MK, Joshi AV, Madhavan SS, et al. Obesity and health-related quality of life: a cross-sectional analysis of the US population. Int J Obes Relat Metab Disord 2003; 27(10): 1227–32PubMedCrossRef Hassan MK, Joshi AV, Madhavan SS, et al. Obesity and health-related quality of life: a cross-sectional analysis of the US population. Int J Obes Relat Metab Disord 2003; 27(10): 1227–32PubMedCrossRef
32.
Zurück zum Zitat Talbot F, Nouwen A. A review of the relationship between depression and diabetes in adults: is there a link? Diabetes Care 2000; 23(10): 1556–62PubMedCrossRef Talbot F, Nouwen A. A review of the relationship between depression and diabetes in adults: is there a link? Diabetes Care 2000; 23(10): 1556–62PubMedCrossRef
33.
Zurück zum Zitat Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Intern Med 2000; 160(21): 3278–85PubMedCrossRef Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Intern Med 2000; 160(21): 3278–85PubMedCrossRef
34.
Zurück zum Zitat Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977; 1: 385–401CrossRef Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977; 1: 385–401CrossRef
35.
Zurück zum Zitat Weissman MM, Sholomskas D, Pottenger M, et al. Assessing depressive symptoms in five psychiatric populations: a validation study. Am J Epidemiol 1977; 106(3): 203–14PubMed Weissman MM, Sholomskas D, Pottenger M, et al. Assessing depressive symptoms in five psychiatric populations: a validation study. Am J Epidemiol 1977; 106(3): 203–14PubMed
36.
Zurück zum Zitat American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005; 28Suppl. 1: S4–36CrossRef American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005; 28Suppl. 1: S4–36CrossRef
38.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40(5): 373–83PubMedCrossRef Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40(5): 373–83PubMedCrossRef
39.
Zurück zum Zitat D’Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol 1996; 49(12): 1429–33PubMedCrossRef D’Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol 1996; 49(12): 1429–33PubMedCrossRef
40.
Zurück zum Zitat Arbuckle JL. Amos (version 4.0) [computer program]. Chicago (IL): Smallwaters Corporation, 1999 Arbuckle JL. Amos (version 4.0) [computer program]. Chicago (IL): Smallwaters Corporation, 1999
41.
Zurück zum Zitat Byrne BM. Structural equation modeling with AMOS. Mahwah (NJ): Erlbaum, 2001 Byrne BM. Structural equation modeling with AMOS. Mahwah (NJ): Erlbaum, 2001
42.
Zurück zum Zitat SPSS for Windows Release 14 [computer program]. Chicago (IL): SPSS Inc., 2004 SPSS for Windows Release 14 [computer program]. Chicago (IL): SPSS Inc., 2004
43.
Zurück zum Zitat Sullivan M. The new subjective medicine: taking the patient’s point of view on health care and health. Soc Sci Med 2003; 56(7): 1595–604PubMedCrossRef Sullivan M. The new subjective medicine: taking the patient’s point of view on health care and health. Soc Sci Med 2003; 56(7): 1595–604PubMedCrossRef
44.
Zurück zum Zitat Ware Jr JE, Kosinski M, Bjorner JB, et al. User’s manual for the SF-36 Health Survey (version 2). 2nd ed. Lincoln (RI): QualityMetric Inc., 2006 Ware Jr JE, Kosinski M, Bjorner JB, et al. User’s manual for the SF-36 Health Survey (version 2). 2nd ed. Lincoln (RI): QualityMetric Inc., 2006
45.
Zurück zum Zitat Ware Jr JE, Kosinski M, Bjorner JB, et al. User’s manual for the SF-36v2 Health Survey. 2nd ed. Lincoln (RI): QualityMetric Inc., 2007 Ware Jr JE, Kosinski M, Bjorner JB, et al. User’s manual for the SF-36v2 Health Survey. 2nd ed. Lincoln (RI): QualityMetric Inc., 2007
46.
Zurück zum Zitat Muntaner C, Barnett E. Depressive symptoms in rural West Virginia: labor market and health services correlates. J Health Care Poor Underserved 2000; 11(3): 284–300PubMedCrossRef Muntaner C, Barnett E. Depressive symptoms in rural West Virginia: labor market and health services correlates. J Health Care Poor Underserved 2000; 11(3): 284–300PubMedCrossRef
47.
Zurück zum Zitat Hanninen J, Takala J, Keinanen-Kiukaanniemi S. Quality of life in NIDDM patients assessed with the SF-20 questionnaire. Diabetes Res Clin Pract 1998; 42(1): 17–27PubMedCrossRef Hanninen J, Takala J, Keinanen-Kiukaanniemi S. Quality of life in NIDDM patients assessed with the SF-20 questionnaire. Diabetes Res Clin Pract 1998; 42(1): 17–27PubMedCrossRef
48.
Zurück zum Zitat Davis TM, Clifford RM, Davis WA. Effect of insulin therapy on quality of life in type 2 diabetes mellitus: the Fremantle Diabetes Study. Diabetes Res Clin Pract 2001; 52(1): 63–71PubMedCrossRef Davis TM, Clifford RM, Davis WA. Effect of insulin therapy on quality of life in type 2 diabetes mellitus: the Fremantle Diabetes Study. Diabetes Res Clin Pract 2001; 52(1): 63–71PubMedCrossRef
49.
Zurück zum Zitat Ristic S, Bates PC. Effects of rapid-acting insulin analogs on overall glycemic control in type 1 and type 2 diabetes mellitus. Diabetes Technol Ther 2003; 5(1): 57–66PubMedCrossRef Ristic S, Bates PC. Effects of rapid-acting insulin analogs on overall glycemic control in type 1 and type 2 diabetes mellitus. Diabetes Technol Ther 2003; 5(1): 57–66PubMedCrossRef
50.
Zurück zum Zitat Zhang X, Norris SL, Chowdhury FM, et al. The effects of interventions on health-related quality of life among persons with diabetes: a systematic review. Med Care 2007; 45(9): 820–34PubMedCrossRef Zhang X, Norris SL, Chowdhury FM, et al. The effects of interventions on health-related quality of life among persons with diabetes: a systematic review. Med Care 2007; 45(9): 820–34PubMedCrossRef
51.
Zurück zum Zitat Vinik AI, Zhang Q. Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes. Diabetes Care 2007; 30(4): 795–800PubMedCrossRef Vinik AI, Zhang Q. Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes. Diabetes Care 2007; 30(4): 795–800PubMedCrossRef
Metadaten
Titel
Health-Related Quality of Life and Quality of Life in Type 2 Diabetes
Relationships in a Cross-Sectional Study
Publikationsdatum
01.06.2009
Erschienen in
The Patient - Patient-Centered Outcomes Research / Ausgabe 2/2009
Print ISSN: 1178-1653
Elektronische ISSN: 1178-1661
DOI
https://doi.org/10.2165/01312067-200902020-00008

Weitere Artikel der Ausgabe 2/2009

The Patient - Patient-Centered Outcomes Research 2/2009 Zur Ausgabe

Original Research Article

Paying for Enhanced Service

Pioneer Profile

Jordan Louviere, PhD